Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis
Year: 2021
Type: article
Source: Clinical Investigation
Authors: Fatih M. Uckun, Cemal Orhan, İbrahim H. Özercan, Nurhan Şahin, Joy Powell, Natalie M. Pizzimenti, Michael Völk, Kazım Şahin
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3129502980